GSK and Camp4 partner on neuro and kidney diseases Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 18 December, 2025

Share your perspective. Endpoints is fielding the next Biopharma Sentiment Index (BPSI), a three-minute survey that distills thousands of industry views into a quarterly benchmark. It’s one of the clearest snapshots of how people inside biopharma see the year ahead. Add your voice today.

presented by Strength in rar­i­ty: Why biotech spon­sors are dou­bling down on rare on­col­o­gy con­sor­tia

SPOTLIGHT In Focus Models are out, molecules are in as AI startups sprint to clinic Today at noon: Our 2025 winners and losers list — on Post-Hoc Live

news Lilly’s obesity pill is the first oral GLP-1 to show its worth in the maintenance setting Exclusive: Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis GSK turns to Camp4 for neuro and kidney medicines Moderna lands CEPI as new backer for its pandemic flu program Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic

ENDPOINTS PHARMA European Commission unveils EU Biotech Act as it lags behind other countries  Several companies expected to announce ‘most favored nation’ deals Friday at White House, sources say GSK formally submits new leucovorin indication to FDA for developmental disorder Weakened Biosecure Act poised to become law after Senate passage Novo Nordisk hit with FDA warning letter over acquired Catalent factory RFK Jr. adds conditions to newborn screening list, but future path unclear CDC drops longtime hepatitis B vaccination advice for newborns

in case you missed it 1. Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies 2. RTW's Yarrow to go public in reverse merger with Vyne amid China push 3. Padcev-Keytruda combination notches another bladder cancer win